Microba Life Sciences Ltd
MAP
Company Profile
Business description
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Contact
324 Queen Street
Level 10
BrisbaneQLD4000
AUST: +61 1300974621
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks
Vegemite owner’s shares remain expensive on normalising profits.
Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,051.10 | 25.30 | 0.28% |
| CAC 40 | 8,508.07 | 33.21 | 0.39% |
| DAX 40 | 25,779.31 | 198.43 | 0.78% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,679.03 | 26.16 | 0.25% |
| HKSE | 23,638.24 | 288.21 | 1.23% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,081.46 | 662.61 | -0.95% |
| NZX 50 Index | 13,697.07 | 78.65 | 0.58% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,846.20 | 27.90 | 0.32% |
| SSE Composite Index | 4,032.17 | 11.47 | -0.28% |